Source:http://linkedlifedata.com/resource/pubmed/id/12224581
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
2002-9-12
|
| pubmed:abstractText |
At present, anthelmintic therapy with praziquantel at a dose of 40 mg/kg of body weight is the recommended treatment for control of urinary tract morbidity caused by Schistosoma haematobium. Although this standard regimen is effective, drug cost may represent a significant barrier to implementation of large-scale schistosomiasis control programs in developing areas. Previous comparison trials have established that low-dose (20-30 mg/kg) praziquantel regimens can effectively suppress the intensity of S. haematobium infection in endemic settings. However, the efficacy of these low-dose regimens in controlling infection-related morbidity has not been determined in a randomized field trial. The present random allocation study examined the relative efficacy of a 20 mg/kg dose versus a 40 mg/kg dose of praziquantel in control of hematuria and bladder and renal abnormalities associated with S. haematobium infection in an endemic area of Coast Province, Kenya. After a nine-month observation period, the results indicated an advantage to the standard 40 mg/kg praziquantel dose in terms of reduction of infection prevalence and hematuria after therapy (P < 0.01 and P < 0.005, respectively). However, the two treatment groups were equally effective in reducing structural urinary tract morbidity detected on ultrasound examination. We conclude that in certain settings, a 20 mg/kg dose of praziquantel may be sufficient in providing control of morbidity due to urinary schistosomiasis in population-based treatment programs.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
0002-9637
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
66
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
725-30
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:12224581-Adolescent,
pubmed-meshheading:12224581-Adult,
pubmed-meshheading:12224581-Animals,
pubmed-meshheading:12224581-Anthelmintics,
pubmed-meshheading:12224581-Child,
pubmed-meshheading:12224581-Child, Preschool,
pubmed-meshheading:12224581-Dose-Response Relationship, Drug,
pubmed-meshheading:12224581-Female,
pubmed-meshheading:12224581-Follow-Up Studies,
pubmed-meshheading:12224581-Geography,
pubmed-meshheading:12224581-Hematuria,
pubmed-meshheading:12224581-Humans,
pubmed-meshheading:12224581-Kenya,
pubmed-meshheading:12224581-Male,
pubmed-meshheading:12224581-Morbidity,
pubmed-meshheading:12224581-Parasite Egg Count,
pubmed-meshheading:12224581-Praziquantel,
pubmed-meshheading:12224581-Rural Population,
pubmed-meshheading:12224581-Schistosoma haematobium,
pubmed-meshheading:12224581-Schistosomiasis haematobia,
pubmed-meshheading:12224581-Time Factors,
pubmed-meshheading:12224581-Treatment Outcome,
pubmed-meshheading:12224581-Urologic Diseases
|
| pubmed:year |
2002
|
| pubmed:articleTitle |
Randomized comparison of low-dose versus standard-dose praziquantel therapy in treatment of urinary tract morbidity due to Schistosoma haema tobium infection.
|
| pubmed:affiliation |
Department of Medicine, Case Western Reserve University and University Hospitals of Cleveland, Ohio 44106-4983, USA. chk@po.cwru.edu
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|